BioCryst Pharmaceuticals Inc.

10/02/2024 | Press release | Distributed by Public on 10/02/2024 05:56

BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome